MA38453B1 - Identification of a patient's response to an administration of a s1p receptor modulator - Google Patents

Identification of a patient's response to an administration of a s1p receptor modulator

Info

Publication number
MA38453B1
MA38453B1 MA38453A MA38453A MA38453B1 MA 38453 B1 MA38453 B1 MA 38453B1 MA 38453 A MA38453 A MA 38453A MA 38453 A MA38453 A MA 38453A MA 38453 B1 MA38453 B1 MA 38453B1
Authority
MA
Morocco
Prior art keywords
patient
ethyl
benzyloxyimino
azetidine
trifluoromethyl
Prior art date
Application number
MA38453A
Other languages
French (fr)
Other versions
MA38453A1 (en
Inventor
Hubert Borell
Anne Gardin
Yi Jin
Eric Legangneux
Mike Ufer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/EP2013/058226 external-priority patent/WO2014161606A1/en
Publication of MA38453A1 publication Critical patent/MA38453A1/en
Publication of MA38453B1 publication Critical patent/MA38453B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé d'évaluation de la dose thérapeutique appropriée d'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique à administrer à un patient qui en a besoin, comprenant les étapes consistant à : (i) tester si le patient possède ou non le mauvais génotype métaboliseur; et (ii) si le patient ne possède pas le mauvais génotype métaboliseur, administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient à la dose thérapeutique habituelle; et (iii) si le patient possède le mauvais génotype métaboliseur, ou (a) administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient à une dose thérapeutique inférieure à celle de la dose thérapeutique habituelle; ou (b) ne pas administrer l'acide 1-{4-[1-(4-cyclohexyl-3-trifluorométhyl-benzyloxyimino)-éthyl]-2-éthyl-benzyl}-azétidine-3-carboxylique, ou un sel de celui-ci acceptable sur le plan pharmaceutique, au patient.The invention relates to a method for evaluating the appropriate therapeutic dose of 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine-3 -carboxylic agent to be administered to a patient in need, comprising the steps of: (i) testing whether or not the patient has the wrong metabolizing genotype; and (ii) if the patient does not have the wrong metabolizing genotype, administer 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine -3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the usual therapeutic dose; and (iii) if the patient has the wrong metabolizing genotype, or (a) administering 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose lower than that of the usual therapeutic dose; or (b) do not administer 1- {4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl} -azetidine-3-carboxylic acid, or a salt of it is pharmaceutically acceptable to the patient.

MA38453A 2013-04-04 2013-04-19 Identification of a patient's response to an administration of a s1p receptor modulator MA38453B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808406P 2013-04-04 2013-04-04
PCT/EP2013/058226 WO2014161606A1 (en) 2013-04-04 2013-04-19 Identifying patient response to s1p receptor modulator administration

Publications (2)

Publication Number Publication Date
MA38453A1 MA38453A1 (en) 2016-10-31
MA38453B1 true MA38453B1 (en) 2017-07-31

Family

ID=58501222

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38453A MA38453B1 (en) 2013-04-04 2013-04-19 Identification of a patient's response to an administration of a s1p receptor modulator
MA40098A MA40098A1 (en) 2013-04-04 2017-03-08 Identification of a patient's response to administration of a s1p receptor modulator.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA40098A MA40098A1 (en) 2013-04-04 2017-03-08 Identification of a patient's response to administration of a s1p receptor modulator.

Country Status (1)

Country Link
MA (2) MA38453B1 (en)

Also Published As

Publication number Publication date
MA38453A1 (en) 2016-10-31
MA40098A1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
Janicak et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study
Tiseo et al. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee
Späth et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia
PH12015502291A1 (en) Identifying patient response to s1p receptor modulator administration
Gommoll et al. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
BR112014007357A2 (en) therapeutic monitoring methods of nitrogen scanning drugs
EA200801369A1 (en) METHODS OF TRANSDERMAL ADMINISTRATION OF THE INDONSEROTONIN RECEPTOR AGONIST AND TRANSDERMAL DOSAGE FORM FOR USE OF THIS METHOD
Demirel et al. Comparison of patient‐controlled analgesia versus continuous infusion of tramadol in post‐cesarean section pain management
JP2017519008A5 (en)
Lee et al. Hyperprolactinemia induced by low‐dosage amisulpride in Korean psychiatric patients
MA40098A1 (en) Identification of a patient's response to administration of a s1p receptor modulator.
Riccó et al. Cardiovascular effects of orotracheal intubation following anesthetic induction with propofol, ketamine-propofol, or ketamine-diazepam in premedicated dogs
Usta et al. Diphenhydramine use in the treatment of risperidone-induced sialorrhea
Collister et al. Overexpression of copper/zinc superoxide dismutase in the median preoptic nucleus improves cardiac function after myocardial infarction in the rat
Schmidt et al. P249 Effect Size Of Open-label Versus Double-blind Administration Of Tiotropium In Trials Investigating Health-related Quality Of Life In Copd
Thomas et al. The impact of cannabis use on the dosage of antipsychotic drugs for patients admitted on the psychiatric ward at the University Hospital of the West Indies
Umbricht et al. A double-blind placebocontrolled study of the antidepressant effects of the mGlu2 negative allosteric modulator RG1578 in patients with inadequate response to antidepressant therapy
Ruane‐O’Hora et al. Effect of clazosentan, a selective endothelin A receptor antagonist, and tezosentan, a dual endothelin A/B antagonist, on pulsatile shear stress induced constriction of the iliac in the anaesthetized pig
Grotsch Flupentixol/olanzapine/sulpiride/thioridazine
Mangoni Check for The Impact of Ageing on Pharmacokinetics Arduino A. Mangoni and Elzbieta A. Jarmuzewska
Pathak et al. Comparative study on xylazine, bupivacaine and buprenorphine with ketamine as lumbosacral spinal analgesia in uremic buffalo calves
Werremeyer Retrospective review of a case of serotonin syndrome after discontinuation of risperidone: Was withdrawal neuroleptic malignant syndrome missed?
Singh et al. Effect of ondansetron on sensory level produced by intrathecal bupivacaine
MA38310A1 (en) Combination drug comprising phenylephrine and paracetamol
Pradelli et al. Losartan: il valore clinico ed economico